PACS Group stock has dropped nearly 33% since Monday following a scathing report from a forensic financial firm that accused the newly public company of “scamming” the government and investors.
Topline data from pivotal Phase 3 TANDEM trial now expected in 4Q 2024 due to faster than expected enrollment – – On-track to report topline data from pivotal Phase 3 BROADWAY trial in 4Q 2024 – – ...
(NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the third ... “The payor innovation strategy continues to foster Medicare Advantage growth ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...
Good morning and thank you for joining us for The ODP Corporation’s third quarter 2024 earnings conference call. This is Tim Perrott, and I’m here with Gerry Smith, our CEO. Also joining us on call ...